Patient Leaflet Updated 10-May-2024 | Idorsia Pharmaceuticals UK Ltd
QUVIVIQ 25 mg film-coated tablets / QUVIVIQ 50 mg film-coated tablets
QUVIVIQ 25 mg film-coated tablets
QUVIVIQ 50 mg film-coated tablets
daridorexant
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What QUVIVIQ is and what it is used for
2. What you need to know before you take QUVIVIQ
3. How to take QUVIVIQ
4. Possible side effects
5. How to store QUVIVIQ
6. Contents of the pack and other information
QUVIVIQ contains the active substance daridorexant, which belongs to the class of medicines called “orexin receptor antagonists”.
QUVIVIQ is to treat insomnia in adults.
Orexin is a substance produced by the brain that helps keep you awake. By blocking the action of orexin, QUVIVIQ enables you to fall asleep faster and stay asleep longer, and improves your ability to function normally during the day.
Ask your doctor if the medicine you are taking prevents you from taking QUVIVIQ.
Talk to your doctor or pharmacist before taking QUVIVIQ if you:
Your doctor may want to monitor how the medicine affects you.
Tell your doctor if you get any of the following side effects while taking QUVIVIQ:
If you have depression and you experience a worsening or have thoughts of harming yourself, call your doctor straight away.
This medicine is not for children and adolescents under 18 years of age because QUVIVIQ has not been tested in this age group.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines because:
Drinking alcohol with QUVIVIQ can increase the risk of impaired balance and coordination.
Avoid grapefruit or grapefruit juice in the evening as they may increase the level of QUVIVIQ in the blood.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
It is not known if QUVIVIQ can harm your unborn baby.
A small amount of QUVIVIQ passes into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with QUVIVIQ.
It is not known if QUVIVIQ affects human fertility.
A period of approximately 9 hours is recommended between taking QUVIVIQ and driving or using machines. Be cautious about driving or using machines in the morning after taking QUVIVIQ. Do not engage in potentially hazardous activities if you are not sure you are fully alert, especially in the first few days of treatment.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Your doctor will advise you on the dose of QUVIVIQ to take.
The recommended dose is one 50-mg tablet of QUVIVIQ per night.
If you have liver problems or take certain other medicines, your doctor may prescribe you a lower dose of one 25-mg tablet of QUVIVIQ per night.
The treatment duration should be as short as possible. The appropriateness of continued treatment will be assessed within 3 months by your doctor and periodically thereafter.
If you take more QUVIVIQ than you should, you may experience excessive sleepiness and muscle weakness. Contact your doctor straight away.
If you forget to take QUVIVIQ at bedtime, then you should not take it later during the night, otherwise you may feel drowsy in the morning. Do not take a double dose to make up for a forgotten tablet.
Treatment with QUVIVIQ can be stopped without a need to gradually reduce the dose, and without harmful effects.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Please talk to your doctor if either of these happen to you.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer require. These measures will help to protect the environment.
The active substance is daridorexant.
QUVIVIQ 25 mg film-coated tablets
Each tablet contains daridorexant hydrochloride, equivalent to 25 mg of daridorexant.
QUVIVIQ 50 mg film-coated tablets
Each tablet contains daridorexant hydrochloride, equivalent to 50 mg of daridorexant.
The other ingredients are:
Tablet cores: Mannitol (E421), microcrystalline cellulose (E460), povidone, croscarmellose sodium (see section 2 “QUVIVIQ contains sodium”), silicon dioxide, magnesium stearate.
Film coating: Hypromellose (E464), microcrystalline cellulose (E460), glycerol, talc (E553), titanium dioxide (E171), iron oxide red (E172), iron oxide black (E172), iron oxide yellow (E172; 50 mg tablets only).
Film-coated tablet (tablet)
QUVIVIQ 25 mg film-coated tablets
Light purple, triangular tablet with 25 on one side, and ‘i’ (Idorsia logo) on the other side.
QUVIVIQ 50 mg film-coated tablets
Light orange, triangular tablet with 50 on one side, and ‘i’ (Idorsia logo) on the other side.
QUVIVIQ is available in blister packs of 10 or 30 film-coated tablets.
Not all pack sizes may be marketed.
This leaflet was last revised in April 2024
20 Eastbourne Terrace, London, W2 6LG, UK
www.idorsia.uk
0800 313 4925
0800 313 4925